Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor - Claus Andersson, PhD, joins Rewind´s Board of Directors Leuven, Belgium, January 25, 2023 --- Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated...

Rewind Therapeutics Appoints Dr. Stephen Burbidge to its Management Team - Former GlaxoSmithKline and Proximagen executive adds to Rewind´s drug discovery and development expertise Leuven, Belgium, November 29, 2022 --- Rewind Therapeutics, a company developing...

Rewind Therapeutics Appoints Irene Knuesel, PhD, as Chief Scientific Officer - Former Roche Head of Neuroimmunology strengthens Rewind´s neuroimmunology and neurodegeneration expertise Leuven, Belgium, October 19, 2022 --- Rewind Therapeutics, a company developing...